Filed: 7/21/2023ACC: 0000950123-23-006232
📋 What this filing means
INTERWEST VENTURE MANAGEMENT CO filed this quarterly 13F‑HR report disclosing 5 equity positions with a total reported market value of $24.52M. This filing provides a transparent view of the manager's long equity holdings as of the quarter end.
5
Positions
$24.52M
Total AUM (reported)
6.46M
Total Shares
Allocation by class
COM$16.56M67.5%
CLASS A COM$7.96M32.5%
Portfolio Concentration
Top 3$23.30M95.0%
4–10$1.22M5.0%
Top 3 weight
95.0%
Top 10 weight
100.0%
Voting Authority Distribution
Total shares with voting rights: 6.46M
Sole
Full voting authority
6.46M
shares
% of voting shares100.0%
Shared
Joint voting authority
0.00
shares
% of voting shares0.0%
None
No voting authority
0.00
shares
% of voting shares0.0%
Investment Discretion (by position count)
Sole5
Shared0
Other0
Dominant voting typeSole · 100.0% of voting shares
Institutional Holdings5
Rows:
PMV PHARMACEUTICALS INC
SOLEShares1.61M
TypeSH
Market value$10.11M
41.23%
Sole
1.61M
Shared
0.00
None
0.00
SERA PROGNOSTICS
SOLEShares2.42M
TypeSH
Market value$7.96M
32.47%
Sole
2.42M
Shared
0.00
None
0.00
THE REALREAL
SOLEShares2.35M
TypeSH
Market value$5.23M
21.32%
Sole
2.35M
Shared
0.00
None
0.00
GLAUKOS CORP
SOLEShares16.35K
TypeSH
Market value$1.16M
4.75%
Sole
16.35K
Shared
0.00
None
0.00
DARE BIOSCIENCE INC
SOLEShares62.06K
TypeSH
Market value$56.5K
0.23%
Sole
62.06K
Shared
0.00
None
0.00
| Issuer | Class | Shares | Type | Value / Portfolio % | Voting — Sole | Shared | None |
|---|---|---|---|---|---|---|---|
PMV PHARMACEUTICALS INCSOLE | COM | 1.61M | SH | $10.11M 41.23% | 1.61M | 0.00 | 0.00 |
SERA PROGNOSTICSSOLE | CLASS A COM | 2.42M | SH | $7.96M 32.47% | 2.42M | 0.00 | 0.00 |
THE REALREALSOLE | COM | 2.35M | SH | $5.23M 21.32% | 2.35M | 0.00 | 0.00 |
GLAUKOS CORPSOLE | COM | 16.35K | SH | $1.16M 4.75% | 16.35K | 0.00 | 0.00 |
DARE BIOSCIENCE INCSOLE | COM | 62.06K | SH | $56.5K 0.23% | 62.06K | 0.00 | 0.00 |